COVID-19 resources & COVID-19 vaccine information

Biomarkers: Free and Bound

Explore Our Assays for PK/PD

Sword Assay for Human IL-1β

Product # SB-HIL1 β02-05

Sandwich ELISA

Sword Assay for Human VEGF

Product # SB-HVEGF02-05

Sandwich ELISA

If you do not see your marker or assay kit listed, or would like to obtain the assay as a customized solution for your project now, you can request more information here.

Utilizing our proprietary Sword Swift™ Method Development Process and Sword Swift™ Detection Reagents, our scientists can develop sensitive quantitative assays to measure the amounts of free or bound drug in preclinical or clinical samples with high accuracy and precision.

For a large molecule therapeutic compound, determining the relative amounts of free and bound drug in a sample can be important step in understanding the drug’s in vivo efficacy.

Sword scientists have developed extensive expertise in the development of quantitative methods to determine the amount of free or bound large molecule therapeutic agents.  Utilizing reagents (antibodies, protein or nucleic acid aptamers) that bind known epitopes or binding sequences on the cellular target of interest, assays that quantitate unbound and bound (or free and total) amounts of a large molecule therapeutic compound can be developed.

Contact us today to discuss how our proprietary Sword Swift™ Method Development Process, Sword Swift™ Detection Reagents, and our scientific method development expertise can be utilized to speed your drug or diagnostic assay development processes.

What is Sword SWIFT?

Our program enables you to get more out of your existing assays to answer critical development questions faster.


Learn more about Sword’s patented technology and how it can be optimally configured for your specific matrix needs.